Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of STAR-101 in Healthy Subjects
NCT04081597Phase 1Withdrawn
- Sponsor
- Acanthas Pharma, Inc.
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in acute myeloid leukemia (AML), sarcoma and glioma comparing STAR-101 with Placebo (2 arms). Primary endpoints: Number of participants with Serious Adverse Events and Number of participants with other (non-serious) adverse events. Planned start Feb 2020; status: withdrawn.
02
Drugs
STAR-101
03
Conditions
acute myeloid leukemia (AML)sarcomaglioma
Beyond the preview
Go deeper on NCT04081597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081597.